CME

This activity is supported by educational grants from Carl Zeiss Meditec, Inc. and Regeneron Pharmaceuticals, Inc.

Best of Retina Forum® 2016 - Diabetic Retinopathy: A Revolution in Treatment Options

Best of Retina Forum® 2016 - Diabetic Retinopathy: A Revolution in Treatment Options

This activity is supported by educational grants from Carl Zeiss Meditec, Inc. and Regeneron Pharmaceuticals, Inc.

Overview

Author(s)/Faculty: Rishi P. Singh, MD; Andrew A. Moshfeghi, MD, MBA; Michael S. Ip, MD; John W. Kitchens, MD
Source: Healio - Ophthalmology Education Lab
Type: LectureArticles/Items: 6
Release Date: 12/13/2016Expiration Date: 12/12/2017
Credit Type: CMENumber of Credits: 2
Cost: FreeProvider: Vindico Medical Education
Diabetic retinopathy (DR) is an insidious, progressive disease. Diabetic macular edema (DME), which can occur at any stage of DR, is the most frequent cause of blindness in diabetic eye disease. Although highly effective intravitreal therapy with steroids or biologics has been available for some time to treat DME, options for DR have been limited. The recent approval of intravitreal anti-vascular endothelial growth factor therapy for DR represents the first opportunity for clinicians to use a medical approach to treating the condition. The agents ranibizumab and aflibercept were approved for this indication by the US Food and Drug Administration because of their ability to slow or reverse the course of DR. In this CME activity,Best of Retina Forum® 2016 - Diabetic Retinopathy: A Revolution in Treatment Options, leading clinicians will provide a state-of-the-science review to further clinicians' understanding of the latest data, as well as clinical recommendations for DR and diabetic eye disease and how they should be implemented in practice. New tools and imaging techniques for use in assessing and monitoring patients with diabetic eye disease will also be reviewed.

CME Information

page 1 of 9